- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
U‑Blox and KPN Settle Patent Dispute And Sign Patent License Agreement
Recently, U‑Blox AG and U-blox America Inc. (“u-blox”), announced that it has entered into a worldwide, non-exclusive, patent license agreement with Koninklijke KPN N.V., (“KPN”), for a defined term while settling their ongoing patent disputes. The patent license agreement covers the sale of u‑blox products and services that KPN believes to be essential for telecommunication … Continue reading U‑Blox and KPN Settle Patent Dispute And Sign Patent License Agreement
Read more »Advantages of Patent Valuation
Patents are the core asset generator for various industries. Industries and companies earn a lot through licensing and assigning patents. The license and assignment of patents are common practices in the market which makes the licensor earn millions of royalties. With the rapid technology development and increasing users around the world, the trends of licensing … Continue reading Advantages of Patent Valuation
Read more »Sun Pharma and Celegene Settle Patent Dispute over Lenalidomide (Revlimid®)
Settling an over three old patent infringement dispute, Indian pharmaceutical major, Sun Pharmaceuticals and its subsidiary, including US subsidiary (“Sun”), has reached a settlement with Celgene Corporation (“Celgene”), a subsidiary of pharmaceutical major Bristol Myers Squibb (BMS), to resolve and settle the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a … Continue reading Sun Pharma and Celegene Settle Patent Dispute over Lenalidomide (Revlimid®)
Read more »